stk-012
Recombinant proteinexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05098132)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- DNA Mismatch Repair · Phase 1
- Esophageal Neoplasms · Phase 1
- Melanoma · Phase 1
- Microsatellite Instability · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Interleukin-2 receptor alpha chainPARTIAL AGONIST
IL2RA partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05098132 | Phase 1 | Dec 31, 2021 | Synthekine |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synthekine | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1